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Abstract
BACKGROUND: Ephrin B2 receptor (EphB2) is a target of the canonical wnt pathway implicated in colorectal carci-
nogenesis, and its down-regulation may be associated with adverse prognosis. We evaluated its prognostic value
in resected colon cancer stratified by microsatellite status and other clinicopathologic characteristics. METHODS:
We identified all cases of resected stage III colon cancer from 1995 to 2009 managed in the Capital Health district
of Nova Scotia. Tissue microarrays were constructed and immunohistochemistry (IHC) for tumor EphB2 staining
assigned into quartiles. Microsatellite status was evaluated by IHC for MutL homolog 1 (MLH1) and MutS homolog
2 (MSH2). Microsatellite stable tumors were defined as both MLH1/MSH2 (+/+); tumors staining otherwise were
classified with microsatellite instability (MSI-H). Primary and secondary outcomes were disease-free survival (DFS)
and overall survival (OS), respectively. RESULTS:We identified 159 cases with sufficient tissue for microarray analysis
having a median follow-up of 3.47 years (range, 0.14-14). Median age was 61, 52%were male, 40% had an event, and
29% died. MSI-H was present in 18 (13%). Univariate analysis of EphB2 expression on DFS and OS showed a hazard
ratio (HR) of 2.00 (P= .01) and 2.14 (P= .03), respectively. Multivariate analysis of EphB2 expression on DFS and OS
showed an HR of 2.24 and 2.23, respectively, with tumor IHC ≤ 50%. CONCLUSIONS: In this cohort, decreased
EphB2 expression was an independent prognostic factor for recurrence and death andmay have prognostic relevance
in tumors with MSI-H. However, this would require prospective validation in a larger study.
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Introduction
Treatment advances for colorectal cancer have changed significantly
over the last decade in both early-stage and metastatic settings. How-
ever, colorectal cancer remains one of the leading causes of mortality,
with rectal cancer having a worse stage-specific prognosis than colon
cancer. Despite the development and adoption of targeted systemic
therapies for metastatic disease, the median survival remains less than
2 years, consumes significant healthcare resources, and is associated
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with rising treatment costs [1–5]. A patient selection strategy that is
currently lacking is one that may further guide systemic therapy by
stratifying patients based on their tumor biology as well as stage-specific
prognosis. This may allow foregoing adjuvant chemotherapy in some
patients with a sufficiently good prognosis or, conversely, treating those
with higher stage-specific risk.
Significant progress has been made in solid tumor oncology with
the identification of biologically distinct cancer-specific subsets. The
application of this knowledge to treatment decision-making has led
to clinically improved patient outcomes in metastatic colorectal can-
cer; testing specific k-RAS mutations for epidermal growth factor
receptor inhibitor therapy is one example [6,7]. Furthermore, colon
cancer has two dominant models of carcinogenesis, the microsatellite
instability pathway and chromosomal instability, almost exclusive of
each other [8,9]. Testing tumors for expression of the mismatch re-
pair proteins MutL homolog 1 (MLH1), MutS homolog 2 (MSH2),
MutS homolog 6 (MSH6), and postmeiotic segregation increased 2
(PMS2) by immunohistochemistry (IHC) is a practical way to assess
microsatellite instability. In lymph node–positive colon cancer, obser-
vational studies and retrospective analyses of randomized clinical trials
demonstrate an improved prognosis for tumors with high levels of
microsatellite instability (MSI-H) and reduced benefit from adjuvant
chemotherapy [10,11].
Ephrins were initially identified when screening for a tyrosine
kinase domain of the viral oncogene v-fps [12]. Their roles are diverse
but are largely related to maintaining homeostasis of the cellular
environment, particularly in cellular orientation, motility, and micro-
vasculature [13–17]. The diverse roles of ephrin signaling in the
regulation of cell migration and tissue assembly have led to their study
in multiple fields, including the pathogenesis of solid tumors. The
ephrin B2 receptor (EphB2) is a subtype of the ephrin receptor family,
the largest receptor tyrosine kinase family of transmembrane proteins.
EphB2 is a multifunctional tyrosine kinase receptor that has showed
prognostic significance in various tumor types, including colorectal
cancer [15,18–20]. The extracellular domain is capable of recognizing
signals from the cells’ environment and influencing cell-cell interaction
and cell migration. Preclinical evidence and observational studies
have shown that progressive loss of functional EphB2 may be asso-
ciated with a worse prognosis in multiple stages of colorectal cancer
[18,19,21]. EphB2 is also believed to be a tumorigenic marker in
colorectal cancer [22]. However, the largest clinicopathologic correla-
tive study on EphB2 as a prognostic factor for colorectal cancer had
evaluated patient cohorts with both colon and rectal cases analyzed
together, limited information on systemic therapy, and mixed disease
stages [23]. We conducted a single-center retrospective study of the
prognostic value of EphB2 in patients with resected lymph node–
positive colon cancer. Common clinical and pathology data were col-
lected, and individual patients’ microsatellite status was assessed on the
basis of the premise of differing carcinogenic pathways.
Methods
Patients and Data Collection
We identified all cases of Union for International Cancer Control
stage III colon cancer at the Capital District Health Authority (CDHA)
from January 1995 toOctober 2009. All relevant clinical and pathology
data were collected and abstracted from patients’ medical records. For
study inclusion, patients must have received ≥67% total planned
dose of 6 months adjuvant chemotherapy. Cases without positive
lymph nodes, or those with mesenteric or small omental tumor de-
posits without lymph node involvement (i.e., nodal stage N1c), were
excluded. No patients received neoadjuvant chemotherapy. Pathology
specimens were reviewed centrally at the Queen Elizabeth II Health
Sciences Centre, and two pathology reviewers (T.A. and W.Y.H.) were
blinded to outcomes. On the basis of these criteria, 159 cases had
sufficient tissue for microarray analysis and constitute our target cohort.
This study was approved by the CDHA Research Ethics Board (File
No. CDHA-RS/2011-048).
Tissue Microarray and IHC Analysis
Original hematoxylin and eosin slides from all cases were reviewed
to confirm the diagnosis of colon adenocarcinoma. Tissue micro-
arrays including triplicate 0.5-mm or duplicate 2-mm punches were
constructed from formalin-fixed tissue in archived paraffin wax
blocks. The 0.5-mm punches were collected using the Manual Tissue
ArrayerMTA-1 (Beecher Instruments, Sun Prairie, WI), and the 2-mm
punches were collected using the Tissue-Tek Quick-Ray Microarray
System (Sakura Finetek, Torrance, CA). IHC stains for MLH1
(G168-15; BD Pharmingen, Franklin Lakes, NJ), MSH2 (FE11;
BD Pharmingen), MSH6 BC/44 (Biocare Medical, Concord, CA),
and PMS2 EPR3947 (Cell Marque, Rocklin, CA) were applied to
5-μm sections according to our previously published protocol [24].
IHC staining for EphB2 was performed manually as follows. After
dewaxing and rehydration, sections were pretreated with peroxidase
blocking buffer (120 mM Na2HPO4, 43 mM citric acid, 30 mM
NaN3, 0.2% H2O2; pH 5.8) for 15 minutes. Antigen retrieval was
performed by autoclaving sections for 20 minutes at 121°C and
1 atm in 20 mM sodium citrate buffer (pH 6.0). Slides were washed
three times in phosphate-buffered saline (PBS) before blocking for
20 minutes with 0.05% BSA Fraction V (Roche, Indianapolis, IN).
Slides were washed three times in PBS and incubated with goat
anti-EphB2 (AF467; R&D Systems, Minneapolis, MN) at 1:200 dilu-
tion in 0.05% BSA at 4°C. Sections were washed three times in PBS
and incubated with rabbit anti-goat IgG (Jackson ImmunoResearch,
West Grove, PA) for 1 hour at room temperature at 1:5000 dilution
in 0.05% BSA, followed by incubation with Powervision HRP anti-
rabbit IgG (Novocastra/Leica Microsystems, Wetzlar, Germany)
for 45 minutes at room temperature. Slides were washed in PBS,
developed with DAB, and counterstained with hematoxylin.
IHC stains were interpreted by consensus of two study authors
(T.A. and W.Y.H.). The stains were interpreted independently by
each reviewer, and in cases where there was disagreement on indepen-
dent review, a consensus was reached by a secondary review of both
pathologists together using a multiheaded microscope. MLH1,
MSH2, MSH6, and PMS2 expression was considered intact when
any proportion of the tumor cells showed nuclear staining. Loss of
expression of MLH1, MSH2, MSH6, and PMS2 was defined as com-
plete loss of nuclear expression in the tumor cells when internal control
lymphocytes and stromal cells had appropriate nuclear immuno-
positivity. EphB2 staining was interpreted on the basis of the propor-
tion of cells with complete membrane staining of any intensity. The
proportion of tumor cells with EphB2 immunopositivity was deter-
mined by visual estimation at ×200 magnification. The proportion
of immunopositive cells for each case was recorded in one of four
quartiles: 0% to 25%, 26% to 50%, 51% to 75%, or 76% to
100% positive tumor cells. Benign colonic mucosal cells at the base
of the crypts with complete membrane staining served as internal
positive controls for EphB2, while surface epithelial cells served as
Translational Oncology Vol. 6, No. 5, 2013 Ephrin B2 Receptor and Microsatellite Status Drucker et al. 521
internal negative controls. In tumors with loss of any mismatch re-
pair protein by IHC, DNA analysis for microsatellite instability was
performed according to our previously published protocol [24]. We
interpreted tumors with instability at greater than or equal to two
mononucleotide loci (≥40%) as having a high rate of microsatellite
instability (MSI-H). Cases with instability at a single locus (20%) were
classified as low probability of MSI-H. Cases without instability at any
locus were categorized as microsatellite stable (MSS).
Statistical Considerations
Time-to-event analysis, either last known follow-up, first docu-
mented cancer recurrence, or death, was performed by the Kaplan-
Meier method. Disease-free survival (DFS) was defined as the time
from surgical tumor resection to recurrence or death, and overall
survival (OS) was defined as the time from surgery to death. The
log-rank test was performed to compare survival outcomes in groups
stratified by EphB2 and microsatellite status.
The correlation between clinicopathologic characteristics and DFS
or OS was examined using a univariate Cox proportional hazards
model and tested for significance (Table 2). Proportional hazards
assumption for each variable was tested by using the supremum test,
graphical assessment using the log-negative-log survival curves to test
for parallelism and plots of the Schoenfeld residuals. Continuous
variables were tested for linearity on the log hazard scale.
Only variables that met the proportionality assumption and were
significant at P < .2 were entered into the multivariate model (Table 2).
Variables entered into the final multivariate model were chosen
using stepwise selection. The final model was then tested for overall
goodness-of-fit test [25].
Results
Patient demographics, EphB2, and microsatellite data were sum-
marized using descriptive statistics performed with SAS software ver-
sion 9.2. The clinical and pathologic characteristics of the target
cohort are shown in Table 1A, and common clinicopathologic
associations with EphB2 are summarized in Table 1B. Eighteen of
159 tumors showed loss of expression of one or more of the mismatch
repair proteins MLH1, MSH2, MSH6, and PMS2 by IHC. An ex-
ample of loss of mismatch repair proteins is shown in Figure 1. The
tumors with loss of mismatch repair proteins were all tested for micro-
satellite instability and confirmed to be MSI-H. The tumor tissue
specimens demonstrated marked variation in the proportion of cells
with complete membrane staining for EphB2, ranging from complete
absence of staining in all tumor cells to uniform immunopositivity for
EphB2 in essentially all tumor cells (Figure 2). The median age was
61.5 and distributed almost equally between genders. Nearly 40% of
patients had a recurrence, with the proportion of isolated metastases
only to the liver or lung at 30% and 13%, respectively. The majority
of cases were typical adenocarcinoma and had invasion at least into the
muscle layer, with most having N1 disease. Almost two thirds were
scored as having an intermediate tumor grade. Eighty percent received
either adjuvant 5-fluorouracil (5-FU) or raltitrexed chemotherapy.
DFS and OS for the study cohort are shown in Figure 3.
Table 1A. Patient Characteristics and EphB2 Clinicopathologic Factors.
N Percentage
Gender
Male 82 52
Female 77 48
T stage
T1 or T2 24 15
T3 or T4 135 85
N stage
N1 112 70
N2 46 29
Missing 1 1
Tumor grade
I—Well 16 10
II—Moderate 102 64
III—Poor 36 22
Missing 5 3
Histologic subtype
Adenocarcinoma 135 85
Mucinous 21 13
Signet ring carcinoma 2 1
Missing 1 1
Chemotherapy regimen
5-FU or raltitrexed 127 80
Capecitabine 16 10
FOLFOX 16 10
Location
Left 72 45
Right 72 45
Transverse 12 8
Missing 3 2
Surgical margins
Negative 146 92
Positive 7 4
Missing 6 4
Proportion of EphB2 tumor staining (%)
0-25 65 40
26-50 19 12
51-75 35 22
76-100 40 25
Microsatellite status
Stable (MSS) 141 89
Unstable (MSI-H) 18 11
Table 1B. EphB2 Associations with Clinicopathologic Factors.
EphB2 Expression P Value
Low (0-50%) High (51-100%)
N Percentage N Percentage
Cases 84 52 75 48
Age .62*
Median 61.34 – 61.49 –
Gender .92
Male 84 51.19 52 39
Female 41 48.81 48 36
T stage .46
T1 or T2 11 13.1 13 17.33
T3 or T4 73 86.9 62 82.67
N stage .45
N1 61 73.49 51 68
N2 22 26.51 24 32
Tumor grade .08
Grade I or II 59 71.08 59 83.1
Grade III 24 28.92 12 16.9
Histologic subtype .63
Adenocarcinoma NOS 72 86.75 63 84
Mucinous 10 12.05 11 14.67
Location .15†
Left 35 42.68 37 50
Right 37 45.12 35 47.3
Transverse 12 10 2 2.7
Microsatellite status .45
Stable (MSS) 73 86.9 68 90.7
Unstable (MSI-H) 11 13.1 7 9.3
*t test performed.
†Global P value from logistic regression.
522 Ephrin B2 Receptor and Microsatellite Status Drucker et al. Translational Oncology Vol. 6, No. 5, 2013
Figure 1. Mismatch repair protein IHC. (A) IHC staining shows absence of nuclear expression of MLH1 in malignant glands, while
internal control lymphocytes and stromal cells have intact MLH1 immunopositivity. (B) The same tumor displays loss of PMS2 in tumor
cell nuclei. (C) IHC staining for MSH2 in the same tumor shows intact nuclear expression. (D) Intact MSH6 in the same case. Original
magnification, ×200 (A–D).
Figure 2. EphB2 IHC. (A) IHC staining for EphB2 in normal colonic mucosa shows complete membrane staining at the base of the crypts,
which is lost toward the mucosal surface (original magnification, ×100). (B) Adenocarcinoma with loss of EphB2 expression infiltrates be-
tween several mucosal crypts that retain strong EphB2 expression and serve as an internal positive control (original magnification, ×200).
(C) A different tumor with diffuse EphB2 expression (original magnification, ×100). (D) The same tumor at higher magnification highlights
the complete membranous EphB2 staining pattern (original magnification, ×400).
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Our data show a statistically significant improvement in DFS and
OS in patients whose tumors expressed EphB2 and worse survival
outcomes with lower expression (Figures 4 and 5). EphB2 cases with
≤50% of tumor IHC staining represented 52% of the study cohort.
The data demonstrate a correlation with 5-year DFS of 80%, 67%,
57%, and 38% and 5-year OS of 86%, 63%, 77%, and 57%
corresponding to tumor EphB2 IHC in categorical quartiles of
76% to 100%, 51% to 75%, 26% to 50%, and 0% to 25%, respec-
tively. Relative to other quartiles, there are fewer subjects in the 26%
to 50% quartile grouping (n = 19), and only four died in this group
and six died or recurred. The actual frequency of mortality is higher
in this group than seen in the 51% to 75% quartile, where 10 of 35
subjects died and 15 of 35 subjects had a death or reoccurrence
event. DFS and OS outcomes stratified by both EphB2 and micro-
satellite status are shown in Figure 5, which demonstrate a statis-
tically significant improved survival in those with >50% EphB2
expression in the MSS subset. Observed OS and DFS in MSI-H
tumors were better than those having MSS tumors; however, these
outcomes are not statistically significant as the subset of patients with
MSI-H comprised 18 patients, and after 5 years of follow-up, there
are very few events and patients at risk. In a separate exploratory
analysis, MSI-H was associated with tumor location and grade, with
72% of these tumors being right sided and 60% high grade. The
association of EphB2 and grade as well as to tumor location is also
Figure 3. Target cohort DFS (top) and OS (bottom).
Figure 4. DFS (top) and OS (bottom) stratified by EphB2 quartiles.
Figure 5. DFS (top) and OS (bottom) stratified by EphB2 and
microsatellite status.
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suggested in Table 1B; however, they do not reach the level of sta-
tistical significance. Analysis of IHC for PMS2 showed no discor-
dance in any cases of intact expression of MLH1 (data not shown).
Univariate and multivariate analyses for DFS and OS are summa-
rized in Table 2. Except for age and microsatellite status, their associ-
ation on a number of factors correlated with DFS and OS, including
EphB2 expression. Multivariate analyses using the stepwise model for
DFS and OS show that EphB2 down-regulation, at a median thresh-
old of 50% immunostaining, is an independent prognostic factor for
recurrence and death with similar proportional hazards for each out-
come. Higher nodal stage was the only other variable to demonstrate
an independently worse prognosis in multivariate analysis for both
DFS and OS.
Discussion
In this retrospective study, we evaluated the prognostic significance of
EphB2 in a uniform cohort of stage III treated colon cancer patients.
This was done to minimize potential confounding factors, make the
target cohort more clinically homogeneous, and facilitate collection of
recurrence data. After accounting for common clinical and pathologic
factors, both univariate and multivariate analyses on DFS and OS
demonstrate that down-regulation of EphB2 is an independent prog-
nostic factor for recurrence and death (Table 2). In multivariate analy-
ses, the nodal stage was the only other independent prognostic factor
associated with both outcome end points (Table 2). Age was not
retained in the multivariate model as an independent prognostic fac-
tor for DFS but was retained for OS, which is clinically logical. Older
individuals are more likely to die than younger ones independent of
other factors; however, age alone would not be expected to have an
independent association on recurrence. Tumor location was observed
to be independently associated with DFS but not OS in multivariate
analyses, and our speculation is that this may be linked to tumor
microsatellite status. If true, our sample size of patients having MSI-
H tumors is too small and insufficiently powered to show a statistically
meaningful result (Table 1B and Figure 5). For instance, MSI-H tu-
mors with >50% EphB2 expression seemed to have a worse DFS but a
favorable OS. However, after 5 years of median follow-up, the number
at risk in this patient subset is only three patients, and interventions
such as conversion surgery of isolated metastases or the occurrence of a
single event would have significant changes to the survival curves.
A number of other studies have examined the prognostic signifi-
cance of EphB2 in colorectal cancer. Although this is a single-center
study, our target cohort’s characteristics appear similar to those in
other Canadian cancer registries [26]. Our data are comparable to
results of a very similar study that showed progressive loss of EphB2
was associated with higher tumor stage and grade, with similar IHC
and scoring system methods to ours (i.e., based on proportion of cells
staining and not intensity of staining). As with our study, this suggests
that loss of function of EphB2 is associated with cancer progression and
consequently an adverse prognosis [21]. Another study that evaluated
normal colorectal epithelium, adenoma, primary adenocarcinoma,
and metastases using IHC showed that decreased expression of EphB2
Table 2. Univariate and Multivariate Analyses.
Univariate Analysis
DFS OS
HR [95% Confidence Interval (CI)] P Value HR (95% CI) P Value
Age (< vs ≥ median) 0.796 (0.477, 1.328) .3824 0.553 (0.301, 1.014) .0557*
Gender (female vs male) 0.645 (0.384, 1.084) .0980* 0.585 (0.317, 1.080) .0865*
T stage (T3/4 vs T1/2) 2.049 (0.880,4.785) .0961* 1.751 (0.689, 1.751) .2388
N stage (N2 vs N1) 2.128 (1.258, 3.597) .0049* 2.114 (1.144, 3.891) .0168*
Grade (III vs I/II) 1.896 (1.097, 3.277) .0219* 1.955 (1.041, 3.671) .0371*
Histology (adenocarcinoma vs mucinous
adenocarcinoma)
0.729 (0.331, 1.608) .4340 0.725 (0.285, 1.844) .4991
Location
Left vs transverse 0.376 (0.168, 0.843) .0492* 0.397 (0.156, 1.007) .1410
Right vs transverse 0.412 (0.187,0.906) – 0.451 (0.181, 1.124) –
Chemotherapy
5-FU/raltitrexed vs capecitabine 1.372 (0.425, 4.431) .2709 1.633 (0.224,12.354) –
FOLFOX vs capecitabine 0.286 (0.030, 2.755) – 0 (0, NA)† .8836
Microsatellite status (MSI-H vs MSS) 1.440 (0.574, 3.611) .4368 5.067 (0.697, 36.826) .1088*
EphB2 (0-50% vs 51-100%) 2.000 (1.149, 3.484) .0143* 2.146 (1.081, 4.261) .0291*
Multivariate Analysis
DFS OS
HR‡ 95% CI P Value HR‡ 95% CI P Value
Age (median = 61) – – –
> vs ≤ Median 2.41 1.32-4.40 .004
N stage
N2 vs N1 2.59 1.51-4.44 <.001 2.56 1.41-4.66 .002
Location
Left vs transverse 0.357 0.158-0.811 .014
Right vs transverse 0.373 0.166-0.837 .017
EphB2 Expression
0-50% vs 51-100% 2.24 1.27-3.93 .005 2.23 1.18-4.27 .014
*Variables significant at P < .2 were considered for multivariate analysis.
†Upper bound of CI cannot be estimated because there are no events in the FOLFOX arm.
‡Reported HRs are for outcome events.
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was associated with a shorter median survival [23]. This was performed
in a cohort of mixed colon and rectal cancers, limited data on systemic
treatment, and mixed stages, which may be confounding factors to
survival outcomes. Most recently, results from a study that investigated
EphB2 and its associated signaling suggested EphB2 as a potential
colonic stem cell marker [22].
The membranous staining pattern of the EphB2 antibody used in
this study was relatively straightforward to interpret by light micros-
copy. However, results similar to another study [21] may be difficult
to reproduce using other clones of an EphB2 antibody. Our group
has previously worked with a different EphB2 antibody clone (rabbit
polyclonal anti-EphB2; Abnova, Taipei, Taiwan). This assay pro-
duced a cytoplasmic staining pattern that typically diffusely stained
all tumor cells, with only differences in the intensity of staining noted
between tumors. Assessment of differences in staining intensity was
difficult, and we had greater concerns about reproducibility of the
results using this clone. The intensity of EphB2 staining with this
polyclonal antibody was not associated with a significant difference
in DFS or OS [27].
While the EphB2 antibody used in the present study has prog-
nostic significance and is less challenging to assess for pathologists,
several issues remain before adoption of this IHC stain as a routine
prognostic marker. Further study is required to formally assess the
intraobserver and interobserver variability in interpretation of the
stain. The present study also used tissue microarrays, which include
a very small (0.5-2 mm) sample of the tumor rather than whole sec-
tions. Previous studies of other IHC stains, such as Her2/neu that
similarly has a membranous staining pattern to EphB2 and is also
quantified according to proportion of positive tumor cells, have shown
greater than 95% correlation between tissue microarray and whole
tissue sections [28]. In spite of the strong performance of tissue micro-
arrays in other studies, a prospective study of EphB2 IHC using whole
tissue sections for IHC is necessary to validate EphB2 as a prognostic
marker for use in routine practice.
We recognize some inherent and potential limitations in this study.
Because the entire cohort was treated with adjuvant chemotherapy, it
is not possible to evaluate the outcomes of treatment of naïve patients.
However, adjuvant chemotherapy has long been the standard of care
for stage III colon cancer, and it would not be feasible to study this
population otherwise as the sample size would be too small. We con-
fined our cohort to patients in the Halifax Regional Municipality or
those treated in CDHA to facilitate optimal collection of recurrence
data because disease-specific incidence and mortality data are collected
by Cancer Care Nova Scotia and the Nova Scotia Provincial Archives,
respectively. A potential disadvantage to geographically constraining
our target cohort may contribute to selection and referral bias.
Conclusions
Ephrin receptors are important transmembrane signaling proteins,
and EphB2 specifically seems to have a significant role in colorectal
epithelial cell localization and motility, as well as the stromal micro-
environment, particularly the vasculature. Down-regulation of these
key functions may account for the observed decrease in survival out-
comes in colorectal cancer, reported in our and other similar studies,
by augmenting invasion and metastasis, and may represent its poten-
tial role as a stem cell maker in colorectal cancer. Further studies with
a larger sample size will be required to examine the potential impact
of MSI-H, particularly because microsatellite instability is believed
to contribute to a different mechanism of carcinogenesis. On the
basis of our results, EphB2 appears to provide relevant prognostic
discrimination in lymph node–positive colon cancer independent of
standard clinical and pathologic factors.
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